The Life Sciences team guided Nektar Therapeutics on its underwritten public offering of $373.8 million of shares of its common stock. Nektar sold 4,062,500 shares of common stock in the offering, which includes 529,891 shares sold upon exercise in full by the underwriters of their option to purchase additional shares of common stock in the offering. The shares of common stock were sold at a public offering price of $92 per share. The gross proceeds to Nektar from the offering were approximately $373.8 million. All of the securities sold in this offering were offered by Nektar.
Goodwin previously advised Nektar Therapeutics on its $460 million public offering announced in February 2026.
Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in one Phase 2b clinical trial in atopic dermatitis, one Phase 2b clinical trial in alopecia areata, and in one Phase 2 clinical trial in type 1 diabetes mellitus. Nektar's pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony-stimulating factor (CSF) protein, NKTR-422.
The Goodwin team was led by Justin Platt, Mitch Bloom, Sam Zucker, Griffin Drake, Dan Liu, Candace Hagey, Elizabeth Mulkey, and Maggie Wong.
For more information on the deal, please read the press release.